GenSpera (OTCQB:GNSZ) Names JPA Health Communications as Its
Agency of Record
SAN ANTONIO - January 6, 2015 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a San Antonio based biotech company that
develops innovative prodrug therapeutics for the treatment of cancer, announced
today that it has named JPA Health Communications as its public relations
agency of record.
By
leveraging its deep expertise in oncology, JPA will handle GenSpera's external
communications for the company and its investigational agent mipsagargin,
currently in Phase II clinical development for patients with liver cancer
(hepatocellular carcinoma) and brain cancer (glioblastoma).
"This is an exciting time for GenSpera
and we are pleased to enlist an agency that understands the complexity of
oncology drug development and the important responsibility of engaging the
patient community," said Craig Dionne, Ph.D., chief executive officer of GenSpera.
JPA Health Communications is an
award-winning communications firm that designs and implements strategic health
campaigns for pharmaceutical, non-profit and government clients. As leaders in
influencer relations, JPA uses a targeted approach to reach the stakeholders
who drive change and deliver measurable results. The agency is headquartered in
Washington, D.C., with offices in London and the biotech center of Cambridge,
Mass.
"We are honored to be selected to
partner with GenSpera at this key time in the company's development," said
Carrie Jones, principal and managing director at JPA Health Communications.
"GenSpera is an excellent cultural fit with our firm and they share our
passion for science and brand communications."
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2015/01061.asp
About GenSpera
GenSpera's technology platform combines a
powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system
that provides for the targeted release of drug candidates within a tumor.
GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA,
which is found at high levels in the vasculature of liver and glioblastoma
cancers, and in the vasculature of almost all other solid tumors. Mipsagargin
is therefore expected to have potential efficacy in a wide variety of tumor
types. The U.S. Food and Drug Administration (FDA) granted Orphan Drug
designation in 2013 for the evaluation of mipsagargin in patients with
hepatocellular carcinoma (liver cancer). Mipsagargin Phase II clinical trials
are underway in both hepatocellular carcinoma and glioblastoma patients (brain
cancer). For more information, please visit the company's website: www.genspera.com or follow us on
Twitter @GenSperaNews. Company presentations are available at: http://www.genspera.com/
Cautionary Statement Regarding Forward
Looking Information
This news release may contain
forward-looking statements. Investors are cautioned that statements in this
press release regarding potential applications of GenSpera's technologies
constitute forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results
or regulatory approvals or clearances, need for future capital, dependence upon
collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties will be detailed
from time to time in GenSpera's periodic reports filed with the Securities and
Exchange Commission.
Disclaimer/Disclosure: The
Investorideas.com newswire is a third party publisher of news and research as
well as creates original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and Linkedintoday plus hundreds
of syndication partners. Our site does not make recommendations for purchases
or sale of stocks or products. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated by featured companies, news submissions, content marketing and
online advertising. Contact each company directly for press release questions.
Disclosure is posted on each release if required but otherwise the news was not
compensated for and is published for the sole interest of our readers.
Disclosure: GNSZ is a previous showcase company which expired on December 18,
2014. Investorideas is long 144 shares
BC Residents and Investor Disclaimer:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment